Novartis Leans into US Market, Drug Pricing Reform Notwithstanding

September 23, 2022

Novartis investors were told that the pharma giant would laser focus on the US market in an event on Thursday, September 22nd. The announcement comes weeks after the US government passed drug pricing reform which critics argued would stifle innovation and investments in the nation. This push would help expand the company’s patient recruitment efforts and invest in its US personnel.

According to Reuters, “Novartis’ aspiration is to “organically build its U.S. business to become a top-five player in the U.S. by 2027,” it said in a statement. It ranked 10th in the U.S. market last year, the company added. Still, Novartis said it aimed to be a top-three player in China, up from fifth place last year among multinational pharma companies, while maintaining leading positions in Germany and Japan.”

To read more, click here.

(Source: Reuters, September 22nd, 2022)

Share This Story!